GSK
Price
$37.56
Change
-$0.31 (-0.82%)
Updated
Apr 2, 03:58 PM (EDT)
Capitalization
88.13B
28 days until earnings call
NVS
Price
$110.76
Change
+$1.15 (+1.05%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
197.93B
27 days until earnings call
Ad is loading...

GSK vs NVS

Header iconGSK vs NVS Comparison
Open Charts GSK vs NVSBanner chart's image
GSK
Price$37.56
Change-$0.31 (-0.82%)
Volume$5.23K
Capitalization88.13B
Novartis AG
Price$110.76
Change+$1.15 (+1.05%)
Volume$35K
Capitalization197.93B
GSK vs NVS Comparison Chart
Loading...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GSK vs. NVS commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Hold and NVS is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (GSK: $37.87 vs. NVS: $109.61)
Brand notoriety: GSK and NVS are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GSK: 100% vs. NVS: 81%
Market capitalization -- GSK: $88.13B vs. NVS: $197.93B
GSK [@Pharmaceuticals: Major] is valued at $88.13B. NVS’s [@Pharmaceuticals: Major] market capitalization is $197.93B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GSK’s FA Score shows that 2 FA rating(s) are green whileNVS’s FA Score has 2 green FA rating(s).

  • GSK’s FA Score: 2 green, 3 red.
  • NVS’s FA Score: 2 green, 3 red.
According to our system of comparison, both GSK and NVS are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GSK’s TA Score shows that 3 TA indicator(s) are bullish while NVS’s TA Score has 3 bullish TA indicator(s).

  • GSK’s TA Score: 3 bullish, 5 bearish.
  • NVS’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, NVS is a better buy in the short-term than GSK.

Price Growth

GSK (@Pharmaceuticals: Major) experienced а -1.84% price change this week, while NVS (@Pharmaceuticals: Major) price change was -0.70% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.44%. For the same industry, the average monthly price growth was -1.53%, and the average quarterly price growth was -6.99%.

Reported Earning Dates

GSK is expected to report earnings on Apr 30, 2025.

NVS is expected to report earnings on Apr 29, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-0.44% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($198B) has a higher market cap than GSK($88.1B). NVS has higher P/E ratio than GSK: NVS (23.38) vs GSK (14.01). NVS YTD gains are higher at: 16.695 vs. GSK (13.202). NVS has higher annual earnings (EBITDA): 18.3B vs. GSK (9.08B). NVS has more cash in the bank: 14B vs. GSK (4.99B). GSK has less debt than NVS: GSK (18B) vs NVS (26.3B). NVS has higher revenues than GSK: NVS (46.7B) vs GSK (30.3B).
GSKNVSGSK / NVS
Capitalization88.1B198B44%
EBITDA9.08B18.3B50%
Gain YTD13.20216.69579%
P/E Ratio14.0123.3860%
Revenue30.3B46.7B65%
Total Cash4.99B14B36%
Total Debt18B26.3B68%
FUNDAMENTALS RATINGS
GSK vs NVS: Fundamental Ratings
GSK
NVS
OUTLOOK RATING
1..100
8483
VALUATION
overvalued / fair valued / undervalued
1..100
8
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
7316
SMR RATING
1..100
4837
PRICE GROWTH RATING
1..100
4743
P/E GROWTH RATING
1..100
1070
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (8) in the Pharmaceuticals Major industry is in the same range as NVS (14). This means that GSK’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (16) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (73). This means that NVS’s stock grew somewhat faster than GSK’s over the last 12 months.

NVS's SMR Rating (37) in the Pharmaceuticals Major industry is in the same range as GSK (48). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.

NVS's Price Growth Rating (43) in the Pharmaceuticals Major industry is in the same range as GSK (47). This means that NVS’s stock grew similarly to GSK’s over the last 12 months.

GSK's P/E Growth Rating (10) in the Pharmaceuticals Major industry is somewhat better than the same rating for NVS (70). This means that GSK’s stock grew somewhat faster than NVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GSKNVS
RSI
ODDS (%)
Bearish Trend 2 days ago
44%
Bearish Trend 2 days ago
41%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
44%
Bearish Trend 2 days ago
46%
Momentum
ODDS (%)
Bearish Trend 2 days ago
52%
Bearish Trend 2 days ago
44%
MACD
ODDS (%)
Bearish Trend 2 days ago
49%
Bearish Trend 2 days ago
44%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
50%
Bearish Trend 2 days ago
42%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
50%
Bullish Trend 2 days ago
44%
Advances
ODDS (%)
Bullish Trend 6 days ago
54%
Bullish Trend 6 days ago
47%
Declines
ODDS (%)
Bearish Trend 10 days ago
52%
Bearish Trend 2 days ago
43%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
52%
Bearish Trend 2 days ago
50%
Aroon
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 2 days ago
38%
View a ticker or compare two or three
Ad is loading...
GSK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AMPY3.860.12
+3.21%
Amplify Energy Corp
TKC6.270.05
+0.80%
Turkcell Iletisim Hizmetleri AS
IHS5.21-0.01
-0.19%
IHS Holding Limited
GLW45.54-0.24
-0.52%
Corning
RLYB0.61-0.04
-6.80%
Rallybio Corp

GSK and

Correlation & Price change

A.I.dvisor indicates that over the last year, GSK has been loosely correlated with NVS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if GSK jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GSK
1D Price
Change %
GSK100%
-2.25%
NVS - GSK
49%
Loosely correlated
-1.68%
PFE - GSK
47%
Loosely correlated
-3.16%
SNY - GSK
40%
Loosely correlated
-2.02%
JNJ - GSK
40%
Loosely correlated
-7.59%
AZN - GSK
38%
Loosely correlated
-1.22%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
-1.68%
GSK - NVS
50%
Loosely correlated
-2.25%
AZN - NVS
48%
Loosely correlated
-1.22%
JNJ - NVS
39%
Loosely correlated
-7.59%
PFE - NVS
38%
Loosely correlated
-3.16%
SNY - NVS
38%
Loosely correlated
-2.02%
More